Results 131 to 140 of about 18,044 (238)
JPGN Reports, Volume 7, Issue 2, Page 301-305, May 2026.Abstract The annual healthcare spending on pediatric inflammatory bowel disease (IBD) has increased over time. The objectives of the study were to investigate the cost of routine laboratory surveillance in pediatric IBD patients during outpatient maintenance biologic infusions and determine their impact on clinical management.
Tanmai Shah +3 more
wiley +1 more source
Biosimilars in der Schweiz : Medizin gegen die steigenden Gesundheitskosten? [PDF]
, 2020 Kobler, Irene +5 more
core +1 more source
Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies
MedComm, Volume 7, Issue 5, May 2026.The mechanism of multiple signaling pathways and their related targeted inhibitors in HCC. (A) The mechanism of Ras/Raf/MEK/ERK signaling pathway and its related targeted inhibitors; (B) the mechanism of PI3K/AKT/mTOR signaling pathway and its crosstalk with other pathways and its related targeted inhibitors; (C) the mechanism of JAK/STAT signaling ...
Penghui He +9 more
wiley +1 more source
Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi +6 more
wiley +1 more source
United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.ABSTRACT Background Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF.
Ailsa Hart +15 more
wiley +1 more source
Biosimilars for Haematologic Malignancies: The Path to Sustainable Care
European Medical Journal Hematology, 2017 The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the developmental differences between biosimilars and their reference products.
Paul Cornes +2 more
doaj
Pharmacogenetics of follicle‐stimulating hormone action in the male
Andrology, Volume 14, Issue 4, Page 1064-1072, May 2026.Abstract Male factor infertility (MFI) is involved in half of the cases of couple infertility. The follicle‐stimulating hormone (FSH) therapy is considered efficient to improve semen parameters and pregnancy rate in patients with idiopathic MFI, following the lesson learned from hypogonadotropic hypogonadism.
Andrea Graziani +7 more
wiley +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
The approaches to the assessment of biosimilarity of biotechnological preparations: quality issues
Регуляторные исследования и экспертиза лекарственных средств, 2018 Due to expiration of patents for most highly demanded biotechnological preparations there is a tendency for the increase in the number of applications for marketing authorisation of biosimilar preparations (biosimilars).
A. N. Mironov +8 more
doaj
Glycosimilarity assessment of biotherapeutics 1: quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept [PDF]
, 2018 K
Borza, Beáta +4 more
core